PDL BioPharma, Inc. (NASDAQ:PDLI)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Results 1 - 20 of 128 : 1 2 3 4 5 6 7 Next »

Recs

0
Member Avatar pagliacci100 (62.46) Submitted: 9/18/2014 2:50:09 PM : Outperform Start Price: $9.57 PDLI Score: -21.49

falling knife - I do intend to own this at whatever the right price turns out to be

Recs

0
Member Avatar johnclanaro (< 20) Submitted: 8/19/2014 8:47:46 PM : Outperform Start Price: $9.46 PDLI Score: -20.91

2d qtr beats on eps, beats on revenue. yields 6.44% at a price of 9.55 per share.

Recs

0
Member Avatar Cabzx (48.47) Submitted: 8/17/2014 1:43:15 PM : Outperform Start Price: $9.33 PDLI Score: -20.48

The large Debt/Equity maybe a turnoff for some, but the company has solid revenues, consistently beating the industry. It has a very high coverage and makes for a consistent buy.

Recs

0
Member Avatar 78taxs (< 20) Submitted: 6/26/2014 11:57:35 AM : Outperform Start Price: $9.61 PDLI Score: -23.91

div 2 years or more.

Recs

0
Member Avatar Orthonormal (83.89) Submitted: 3/12/2014 10:32:22 AM : Outperform Start Price: $7.94 PDLI Score: -11.60

Magic Formula pick 3/21/2012
renewed 3/12/2014

Recs

0
Member Avatar NorbertV (< 20) Submitted: 1/28/2014 5:12:41 PM : Outperform Start Price: $8.54 PDLI Score: -23.96

2 years 33% gain plus excellent dividend. P/E at 5 right now no reason it shouldn't continue up.

Recs

0
Member Avatar TheValueDude (41.47) Submitted: 1/9/2014 5:27:33 PM : Outperform Start Price: $8.24 PDLI Score: -16.81

Screen: Under $10B, Top 10% EBIT/EV, Z Score >1.81

Recs

0
Member Avatar lnlrmtg (< 20) Submitted: 1/8/2014 2:31:12 AM : Outperform Start Price: $8.28 PDLI Score: -17.53

fundamentals

Recs

0
Member Avatar Haugurafpeningum (33.71) Submitted: 1/5/2014 2:24:06 PM : Outperform Start Price: $8.26 PDLI Score: -17.31

porte and zz 1

Recs

0
Member Avatar Stregachess (< 20) Submitted: 10/3/2013 12:07:46 AM : Underperform Start Price: $7.47 PDLI Score: +17.05

Analyst love this stock but the IP can't be controlled they are in for a rough ride. Without patent protection it's all just a dream.

Recs

0
Member Avatar SpartanMAC (< 20) Submitted: 8/28/2013 9:42:49 PM : Outperform Start Price: $7.35 PDLI Score: -19.20

Top 30, 275M minimum market cap.

Recs

0
Member Avatar tgainesphd (63.26) Submitted: 4/18/2013 8:01:13 PM : Outperform Start Price: $6.78 PDLI Score: -17.58

Good growth potential.

Recs

0
Member Avatar Aquinas31 (33.29) Submitted: 4/3/2013 4:56:19 PM : Outperform Start Price: $6.63 PDLI Score: -14.33

Dividends going up, probably hits 8+ by 4th quarter

Recs

0
Member Avatar dunloggin (71.24) Submitted: 2/5/2013 1:45:05 PM : Outperform Start Price: $6.02 PDLI Score: -6.20

Dividend paying stock.

Recs

1
Member Avatar pavlos1971 (99.53) Submitted: 1/2/2013 3:58:59 PM : Underperform Start Price: $5.37 PDLI Score: +9.53

Short in RL@7.31

Recs

0
Member Avatar pdhaag (76.12) Submitted: 10/15/2012 9:18:41 PM : Underperform Start Price: $7.09 PDLI Score: +31.41

Most of it's patents are set to expire between 2014 and 2017, at which point revenue will drop dramatically. It's only a matter of time.

Recs

1
Member Avatar FoxForce5contest (32.47) Submitted: 8/18/2012 9:18:30 PM : Outperform Start Price: $6.28 PDLI Score: -20.15

on 8-18-12 Momentum21 picked PDLI

Recs

0
Member Avatar myfairshare (< 20) Submitted: 8/17/2012 6:04:53 PM : Outperform Start Price: $6.28 PDLI Score: -20.15

I think the royalties are the best position to be in, for the pharmaceutical plays.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:35:17 PM : Outperform Start Price: $5.74 PDLI Score: -14.04

Biotech with solid pipeline

Recs

0
Member Avatar DaveKATL (42.45) Submitted: 5/4/2012 9:05:19 PM : Outperform Start Price: $5.24 PDLI Score: +1.75

Strictly a momentum play. They have no drugs in the pipeline and it doesn't look like they're planning anymore - it's like their just burning this company bright and getting what they can out of it.

Featured Broker Partners


Advertisement